Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AVEO Pharmaceuticals Q3 EPS $(0.09) Beats $(0.18) Estimate, Sales $30.45M Beat $29.55M Estimate

Author: Benzinga Newsdesk | November 07, 2022 05:46pm
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.18) by 50 percent. This is a 70 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $30.45 million which beat the analyst consensus estimate of $29.55 million by 3.04 percent. This is a 100.68 percent increase over sales of $15.17 million the same period last year.

Posted In: AVEO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist